Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease

Patent metadata

Field	Value
Publication number	US-11326147-B2
Application number	US-201916361852-A
Country	US
Kind code	B2
Filing date	Mar 22, 2019
Priority date	Jan 31, 2007
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.

First claim

What is claimed is:

1. A method of treating inflammatory bowel disease (IBD) in a mammalian subject in need thereof, comprising:
administering to said mammalian subject an effective amount of redirected T lymphocytes endowed with Treg cell phenotype and specificity toward a target antigen that is present or expressed at a site of inflammation in the bowel, wherein said target antigen is a lipopolysaccharide (LPS) intestinal bacterial floral antigen, and wherein said redirected T lymphocytes comprise a chimeric nucleic acid molecule, comprising:
(a) a first nucleic acid segment comprising a sequence encoding an extracellular recognition region specific for said target antigen, which region does not comprise an MHC protein extracellular domain, wherein said extracellular recognition region comprises an antibody-derived scFv domain that is specific for said selected target antigen;
(b) a second nucleic acid segment comprising a sequence encoding a transmembrane region; and
(c) a third nucleic acid segment comprising a sequence encoding an intracellular signaling region comprising a combination of T-cell signaling polypeptide moieties, said combination of moieties comprising at least one cytoplasmic domain of a T-cell costimulatory molecule and at least one cytoplasmic T-cell stimulatory domain, and which combination of moieties, when the chimeric nucleic acid molecule is transfected or transduced into a T cell and said extracellular recognition region binds to the target antigen, triggers activation of the transfected or transduced T cell;

wherein said redirected T lymphocytes express, in one single, continuous chain, a chimeric receptor polypeptide comprising the extracellular recognition region, the transmembrane region, and the intracellular signaling region, such that the extracellular region thereof is displayed on the surface of the redirected T lymphocytes.

2. The method of claim 1 , wherein said IBD is Crohn's disease or ulcerative colitis.

3. The method of claim 1 , wherein said extracellular recognition region is linked to said transmembrane region through a flexible spacer.

4. The method of claim 1 , wherein said extracellular recognition region is linked to said transmembrane region through a hinge from a molecule of the immunoglobulin superfamily.

5. The method of claim 4 , wherein said intracellular signaling region comprises the CD3-ζ chain or the FcRγ chain.

6. The method of claim 1 , wherein said intracellular signaling region comprises at least two different cytoplasmic domains of a T-cell costimulatory molecule.

7. The method of claim 1 , wherein said T-cell costimulatory molecule is selected from the group consisting of CD28, OX40, CD40L, 4-1BB, and PD-1.

8. The method of claim 7 , wherein said T-cell costimulatory molecule is CD28.

9. The method of claim 7 , wherein said T-cell costimulatory molecule is 4-1BB.

10. The method of claim 1 , wherein said redirected T lymphocytes further comprise a nucleotide sequence that encodes a polypeptide capable of causing the redirected T lymphocytes to express Foxp3.

11. The method of claim 1 , wherein said redirected T lymphocytes are produced by obtaining a population of T-cells from the mammalian subject to be treated, transfecting said cells with said chimeric nucleic acid molecule and causing the cells to express Foxp3 by
(i) stimulating the transfected cells to induce Foxp3 expression, or
(ii) introducing an exogenous Foxp3-encoding construct into the transfected cells.

12. The method of claim 1 , wherein said redirected T lymphocytes are produced by obtaining a mixed population of T-cells from the mammalian subject to be treated, enriching or purifying Treg cells from the mixed population of T-cells on the basis of the Treg cells' expression of CD4 and CD25 and/or Foxp3, and transfecting said enriched or purified Treg cells with said chimeric nucleic acid molecule.

13. The method of claim 1 , wherein said redirected T lymphocytes are produced by:
(a) obtaining
(i) peripheral blood mononuclear cells,
(ii) peripheral blood lymphocytes,
(iii) T-cells enriched or purified from (i) or (ii), or
(iv) a subset of T-cells enriched or purified from (iii);

(b) exposing the cells obtained in (a), ex vivo, to an amount of TGF-β or other Treg-inducing cytokine or agent that is effective to induce expression of Foxp3 and convert T-cells to a Treg phenotype,
(c) optionally, culturing and expanding said exposed cells of (a); and
(d) before, after, or between said steps (a) and (b), transfecting said cells with said chimeric nucleic acid molecule.

14. The method of claim 1 , wherein said redirected T lymphocytes are administered to said mammalian subject systemically, parenterally, regionally, or locally to a site of inflammation.

15. The method of claim 14 , wherein said parenteral administration comprises intraluminal, intrathecal, intramuscular, intravenous, subcutaneous, intraperitoneal, or intra-articular administration.

16. The method of claim 1 , wherein said mammalian subject is a human.

17. The method of claim 1 , wherein said redirected T lymphocytes are administered at a dosage of about 10 6 to about 10 11 per administration.

Assignees

• Yeda Res & Dev

Inventors

• Eshhar Zelig
• Elinav Eran

Classifications

• A61K40/4205

  Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 · CPC title

• A61K40/416

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/22

  Immunosuppressive or immunotolerising · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title